

## **INFORMED CONSENT FORM**

**Study title:** Does prophylactic antibiotics reduce infectious complications post endoscopic retrograde cholangio pancreatography in common bile duct stones patients: a clinical trial?

### **1. Study Objective**

This study aims to find out if using preventive antibiotics can lower infection rates after ERCP in patients with bile duct stones.

### **2. Participation Procedure**

Participants will be patients with bile duct stones who need ERCP but do not have cholangitis. They will be randomly assigned to one of three groups:

- + Prophylactic Antibiotic Group: Will receive Amikacin (an antibiotic) before the ERCP procedure.
- + Full-dose Antibiotic Group: Will receive Amikacin and a third-generation cephalosporin antibiotic from before the ERCP until hospital discharge.
- + Control Group: Will not receive antibiotics, only normal saline.

After ERCP, patients will be monitored for signs of infection through symptoms and lab tests.

### **3. Benefits and Risks**

- Benefits: This study may help promote the appropriate use of antibiotics during ERCP in patients with common bile duct stones. As a result, it could reduce antibiotic resistance in the community, as well as lower healthcare costs and shorten hospital stays.
- Risks: The main risk of this study is the possibility of allergic reactions in the group receiving antibiotics. In the group not receiving antibiotics, there may be a higher risk of post-ERCP infectious complications.

### **4. Confidentiality**

- Information about your name will be kept confidential. The results of this study may be presented at conferences or published in journals; however, your identity will not be disclosed.

- You have the right to refuse to answer any personal questions.

### **5. Voluntary Participation and Withdrawal**

Participation is entirely voluntary. You may withdraw at any time without affecting your treatment

### **6. Contact Information**

If you have any questions, please contact:

Principal Investigator: Tran Van Thanh

Phone number: +84977157219

### **7. Consent to Participate**

I confirm that I have been clearly informed, understand and voluntarily agree to participate.

Participant's Name: .....

Signature: .....Date: .....

Research Staff: .....

Signature: .....Date: .....